23 results
Thumbnail

- D3.196 - Efficacy of sublingual immunotherapy in children with allergic rhinitis

Thumbnail

D3.193 - Impact of subcutaneous allergen immunotherapy on autoimmune disease development or exacerbations: a cross-sectional study

Thumbnail

D3.194 - Renewal’s analysis of liquid sublingual immunotherapy (SLIT) treatments using iPUMP: SPEED study, a Real-Life study

Thumbnail

D3.195 - Reasons for declining venom immunotherapy and its burden on patients' daily lives

Thumbnail

D3.197 - When is molecular testing necessary? Rethinking allergy diagnostics for Dermatophagoides pteronyssinus

Thumbnail

D3.198 - Hymenoptera Venom Allergy: A Case Report on Safe Discontinuation After Five Years of Venom Immunotherapy

Thumbnail

D3.202 - Allergen-Specific Immunotherapy Is Still Rarely Used: Results of an Online Survey in Lithuania

Thumbnail

D3.203 - Yeast surface display as platform for generation of nanobodies to single allergens and allergen extracts

Thumbnail

D3.204 - Elevated Tryptase Levels in a Severe Asthmatic Patient Undergoing SCIT for Birch: Implications for Monitoring and Personalized Treatment

Thumbnail

D3.205 - Online Education Increases Clinician Knowledge and Confidence in Utilizing Allergen Immunotherapy for Respiratory Allergic Disease

Thumbnail

D2.332 - Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group

Thumbnail

D2.325 - Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study

Thumbnail

D2.326 - Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study

Thumbnail

D2.327 - Outcome of hematopoietic stem cells transplantation for inborn error of immunity in Vietnam

Thumbnail

D2.328 - Comparison of the frequency of viral infections in immunocompromised patients receiving immunoglobulin by different routes

Thumbnail

D2.329 - Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials

Thumbnail

D2.330 - Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile

Thumbnail

D2.331 - Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study

Thumbnail

D2.334 - Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: A 12-Month Retrospective Study at a Single Center in Colombia

Thumbnail

D2.336 - Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)